Download Files:
MYLS22
$34 – $490
Products Details
Product Description
– MYLS22 is a selective optic atrophy 1 (OPA1) inhibitor. MYLS22 inhibits tumor angiogenesis. MYLS22 has anticancer activity[1][2][3].
Web ID
– HY-136446
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C24H21N5O2S
References
– [1]Larrue C, et al. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. Leukemia. 2023 Apr;37(4):765-775.|[2]Schuler MH, et al. OPA1 and Angiogenesis: Beyond the Fusion Function. Cell Metab. 2020 May 5;31(5):886-887.|[3]Herkenne S, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.
CAS Number
– 306959-01-3
Molecular Weight
– 443.52
Compound Purity
– 99.47
SMILES
– O=C(C(S1)=CC2=C1N(C3=CC=CC=C3)N=C2C)NC4=C(C)N(C)N(C5=CC=CC=C5)C4=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Cardiovascular Disease
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Others
Pathway
– Others
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
